News

A ‘Glimmer Of Hope’ In The Fight Against The World’s Top Infectious Killer


27 Sep 2017
by Working Group

In a sign of increasing political will in the battle against the world’s top infectious killer, the heads of the World Health Organization and USAID voiced their support for the global fight against tuberculosis last week in a reception during the United Nations General Assembly.

Advocates had been seeing a snowballing of political support to thwart tuberculosis, first with the announcement of a U.N. high-level meeting focused solely on TB next year, followed by the recent inclusion of the fight against TB in the G-20 declaration and excitement over a WHO ministerial conference on tuberculosis to be headlined by Russian President Vladimir Putin in November.  

WHO Director Tedros Adhanom Ghebreyesus spoke movingly of his brother’s fight against tuberculosis at the reception hosted Sept. 19 by the Stop TB Partnership and WHO, both part of the U.N. He stressed that TB continues to be a major problem today and that antimicrobial resistance is making it even more deadly. 

And the need for new drugs to combat tuberculosis, whose drug-resistant strains account for a third of antimicrobial-resistant (AMR) deaths, is growing. “Drug-resistant TB is the most common and lethal airborne AMR disease worldwide today, responsible for 250,000 deaths each year,” stated the WHO’s “Antibacterial Agents in Clinical Development” report, released last week.

Continue reading at HuffintonPost.com

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...